cyrilzakka/clinical-trials huggingface dataset:
Gait Parameters After Using the Tilt-table Exercise and Motor Imagery.

Sixty-six stroke patients were randomly assigned to three groups (conventional, with the addition of the Erigo®Pro table, and enriched with motor imagery). The Trunk Stability Test, walking speed, step symmetry, and lower limb load symmetry on the Riablo device, as well as the superficial tension of the transverse abdominis and multifidus muscles, were assessed before and after completing therapy.

Sixty-six stroke patients were randomly assigned to three groups (conventional, with the addition of the Erigo®Pro table, and enriched with motor imagery). The Trunk Stability Test, walking speed, step symmetry, and lower limb load symmetry on the Riablo device, as well as the superficial tension of the transverse abdominis and multifidus muscles, were assessed before and after completing therapy.

Results: In each of the groups studied, the therapies used significantly improved the functional assessment of trunk stability (Trunk Control Test \<0.001)). Additionally, after the intervention, the Erigo group showed a greater gait speed (p=0.003), while the Visualization group exhibited a higher level of tension in the multifidus (p=0.011) and transverse abdominal muscles (p=0.002).

Eligibility Criteria:
Inclusion Criteria:

* 1) patients 6-8 weeks post-stroke, 2) aged 38-85 years, mean, 3) males and females, 4) walking with or without assistance (modified Rankin scale = 3), 5) with slight neurological deficits (NIHSS ≤7).

Exclusion Criteria:

* 1) stroke up to six weeks after the episode, 2) epilepsy, 3) no possibility to sit and stand, 4) persistent deficit of speech and cognitive functions, lack of attention, 5) visual disturbances, 6) depression, 7) high or very low blood pressure, dizziness, malaise.
Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response

There is no consensus on the treatment of patients with recurrent infections and isolated immunoglobulin G (IgG)-subclass deficiency and/or selective antipolysaccharide antibody deficiency. Therefore, the Dutch Inter University Working Party will start a study in which the treatment with antibiotics is compared with intravenous immunoglobulin therapy with respect to clinical outcome measures in both children and adults with this disorder.

There is no consensus on the treatment of patients with recurrent infections and isolated IgG-subclass deficiency and/or selective antipolysaccharide antibody deficiency. At present, there are no robust criteria to predict which patient will or will not respond adequately to antibiotic treatment or to IVIG. Furthermore, it is unknown whether IVIG treatment improves the quality of life in these patients. Therefore, the Dutch InterUniversity Working Party intends to start a study in this patient group. In this study, treatment for a year with antibiotics will be compared with a year intravenous immunoglobulin therapy with respect to clinical outcome measures in both children and adults with this disorder.

The patient will visit the clinic every 3 months during which laboratory tests and physiological measurements will be performed. Moreover the occurrence of infections and fever, the use of antibiotics, hospital admissions, and quality of life will be documented.

The study should result in a national harmonization in the treatment of this patient group. To this end, the results of the study will be used to compile a treatment protocol for this group of patients in the Netherlands and if applicable also in other countries worldwide.

Eligibility Criteria:
Inclusion Criteria:

* IgG subclass deficiency and/or (selective) antipolysaccharide antibody deficiency
* At least 2 physician documented infections before the start of the current treatment or in the last 6 months for newly diagnosed patients.
* Total serum IgG \> 4 g/l
* ≥ 5 years of age
* Informed consent

Exclusion Criteria:

* Treatment with any other investigational drug within 7 days prior to study entry, or previous enrolment in this study
* Allergic reactions against human plasma/plasma products, or co-trimoxazole
* An ongoing progressive terminal disease
* Pregnancy or lactation
* History of (transient) cerebrovascular accident or coronary insufficiency
* Renal insufficiency (plasma creatinin \> 115 µmol/L; or creatinin clearance \<20 ml/min)
* An ongoing active disease causing general symptoms e.g. chronic active hepatitis or persistent enterovirus infection with ongoing systemic complaints
* Detectable anti-IgA antibodies
* Active systemic lupus erythematosus (SLE)
* Glucose-6-phosphate hydrogenase deficiency
Clinical, Biological and Histological Pulmonary and Renal Damage Associated With the SARS-CoV-2 Syndrome in Patients Admitted in ICU

Renal damage in patients hospitalized for ARDS in the ICU can also be related to multiple causes including, but not limited to, the consequences of hemodynamic fluctuations in these patients or the use of nephrotoxic drugs responsible for acute post-ischemic or toxic tubular necrosis. Frequently observed abnormalities of cioagumation may also have a potential impact on renal structures, particularly glomerular capillaries.

The researchers wish to characterize and phenotype the renal impairment of patients hospitalized in intensive care with tables of severe Covid19 infections in ARDS: clinical, biological and histological (by performing post-mortem biopsies).

Translated with www.DeepL.com/Translator (free version)


Eligibility Criteria:
Inclusion Criteria:

* Patients over 18 years of age
* Diagnosed Covid-19 by RT PCR
* Hospitalized in intensive care for management of complications related to Covid-19 from March 1, 2020 to April 20, 2020
* Patient not having expressed his or her opposition, after information, to the re-use of his or her data for the purposes of this research.

Exclusion Criteria:

- Subject who expressed opposition to participating in the study
Safety and Tolerability of VGR-R01 in Patients With Bietti Crystalline Dystrophy

An Open-Label, Non-Randomized, Uncontrolled, Single-dose Pilot Study of VGR-R01 in Patients with Bietti Crystalline Dystrophy.

VGR-R01 is a novel AAV vector carrying the human CYP4v2 coding sequence. This study is intended to evaluate the safety and tolerability of a single subretinal administration of VGR-R01. All subjects will undergo 365(±7) days of safety observation and will be encouraged to enroll in an extension study to evaluate the long-term safety of VGR-R01 for a total of five years.

Eligibility Criteria:
Inclusion Criteria:

1. ≥18 years and \<80 years of age;
2. Confirmed diagnosis of Bietti Crystalline Dystrophy;
3. Molecular diagnosis of CYP4v2 mutations (homozygotes or compound heterozygotes);
4. BCVA ≤ 20/200 in the study eye;
5. -8 D \<diopters\< +8 D, 21 mm \< axial lengths ≤ 28 mm in the study eye;
6. Normal liver function and renal function；
7. Agree to use reliable barrier contraception for 1 year after administration of VGR-R01;
8. Able to provide informed consent and comply with requirements of the study. -

Exclusion Criteria:

1. Have insufficient viable retinal photoreceptor cells based on investigator's decision;
2. Have current ocular or periocular infections, or endophthalmitis;
3. Have any significant ocular disease/disorder other than BCD, including age-related macular degeneration, diabetic retinopathy, optic neuropathy, significant lens opacity, glaucoma, uveitis, retinal detachment, etc;
4. Have intraocular surgery history except cataract surgery in the study eye;
5. Prior medications which may interfere with the interpretation of study endpoints within six months before screening, eg. anti-VEGF drugs;
6. Have or potentially require of systemic medications that may cause eye injure;
7. Live attenuated vaccines is expected to be required during the study;
8. Participation in a clinical study with an investigational drug or medical device within three months before enrollment;
9. History of allergy or sensitivity to investigational drug, medications planned for use in the study;
10. Use of anticoagulants, or after 10 days cessation of anti-platelet agents the platelet function does not recover;
11. Use of any corticosteroids, other immunosuppressive drug(s) or antipsychotic drugs (eg. antidepressant, etc.) within 3 months prior to enrollment;
12. Have contraindications for corticosteroids or immunosuppressant;
13. Have complicating systemic diseases that would preclude the planned follow-up;
14. Abnormal coagulation function or other clinically significant abnormal laboratory results;
15. Have malignancies or history of malignancies;
16. History of immunodeficiency (acquired or congenital);
17. Females in lactation period;
18. Have a history of alcohol or illicit drug addiction;
19. Unable or unwilling to comply with the schedule of visits. -
Parameter Changes in Functional Electrical Stimulation

This study aims to look at how changes to a person's functional electrical stimulation might change how they walk. Functional electrical stimulation (FES) is commonly used to help people with foot drop from upper motor neurone conditions such as stroke or multiple sclerosis. This group of people have muscle weakness which makes it difficult to lift the foot, which causes trips and falls.

FES reduces foot drop by using a portable device to apply short electrical pulses to the nerve which lifts the foot. The FES device stimulates this nerve only during the swing phase, when the foot is off the floor. Typically this is achieved by using a foot-switch, which detects when the heel leaves the floor. Stimulation begins a short interval of time after the heel leaves the floor, ramps up from zero to set stimulation for the individual, and at another period of time after the heel hits the floor, stimulation ramps down from set amount to zero. There are four time intervals described here which can be varied by the clinician on the device:-

* Delay (the time between heel lift and the start of stimulation)
* Ramp up (the time for stimulation to reach full strength)
* Extension (the time between heel strike and the ramp down)
* Ramp down (the time for stimulation to reach zero from full strength) These intervals are usually set by experienced clinicians using a qualitative assessment of the patient's walking and trial-and-error. A literature review has found no published studies which compare walking with different timing. This knowledge would be useful for clinicians, who could use this information as a starting point in finding the best timing parameters for each patient.


Eligibility Criteria:
Inclusion Criteria:

* Upper motor neurone lesion causing foot drop
* Currently use single-channel Odstock Medical ODFS functional electrical stimulator
* Age 18 or older
* Attending Leeds FES Service follow-up clinics

Exclusion Criteria:

* • FES user for less than three months

  * Lower limb prosthesis
  * Cannot walk 5m with walking aids
  * Cannot walk twenty 5m walks within a three-hour period
  * Use FES less than once per week
High Intensity Aerobic Training on Primary Dysmenorrhea

Now a days Aerobic Exercise programs has been widely used as non-pharmacological means of treating pain disorders. This study intends to determine the effects of high intensity aerobic training on pain intensity, dysmenorrhea symptoms and quality of life of young girls having primary dysmenorrhea.

This study is a Randomized Control Trial, which will be conducted in Shifa Tameer-e-Millat University (Department of Rehabilitation Sciences). the calculated Sample size is 24 individuals using Epitool with 95% Confidence Interval (CI) and power 80%. Individual will be screened out according to inclusion criteria. Individuals will be allocated randomly into two groups, 12 in High Intensity Aerobic training group and 12 in Low Intensity Aerobic Training group by sealed envelope method. High Intensity Aerobic Training will be use in experimental group. Low Intensity Aerobic Training will be used in Control group. Assessment will be done on baseline day 1 prior to the intervention and after 8 weeks of training.

Eligibility Criteria:
Inclusion Criteria:

* Unmarried female students.
* Moderate to severe dysmenorrhea during the last three periods according to the Numeric Pain Rating Scale.

Exclusion Criteria:

* Presence of known chronic disease (heart disease, kidney, respiratory, asthma, diabetes, nervous disorders, blood pressure), limitation on sports/physical activities due to special medical problems.
* Presence of any disease of reproductive system.
* Irregular monthly cycle.
* Use of any particular medications affecting dysmenorrhea before or during the study.
Effects of Cognitive Correction and Stimulus Control in Chronic Insomnia Patients

This study aims to validate the effect of cognitive correction and stimulus control on correcting sleep cognitive distortions and improving maladaptive sleep behaviors.

Cognitive correction aims to identify and change patients' erroneous beliefs and attitudes about sleep, which may include exaggerated sleep needs, excessive worry about the consequences of insomnia, and unrealistic expectations about bedtime. Stimulus control, on the other hand, focuses on modifying patients' behaviors in bed, linking the bed with a rapid onset of sleep, and reducing the negative association between the bed and insomnia.

Eligibility Criteria:
Inclusion Criteria:

1. Meets the diagnostic criteria for insomnia disorder according to DSM-5;
2. Pittsburgh Sleep Quality Index (PSQI) total score \> 5;
3. Age ≥ 18 years, with at least a junior high school education;
4. Sleep cognitive distortions assessed using the DBAS-16;
5. "Maladaptive Sleep Behavior Questionnaire - 8 items" used to assess "maladaptive sleep behaviors";
6. Willing to participate in the study and sign an informed consent form.

Exclusion Criteria:

1. Presence of severe physical illness or serious mental disorders, or at risk for suicide;
2. Clinically diagnosed or suspected sleep-related breathing disorders, restless legs syndrome, and circadian rhythm sleep-wake disorders; shift workers;
3. Pregnant or lactating women;
4. Currently undergoing any form of psychological therapy.
Impact of Dose to Cardiac Substructures on Survival in Patients With Esophageal Cancer Treated With Radiotherapy or Chemoradiotherapy (SATIATION)

Treatment of non-operable esophageal cancers is based on radiochemotherapy, or exclusive radiotherapy.

The cardiac toxicity of radiotherapy in the treatment of thoracic tumor localizations is well documented, however, more and more studies are calling for the use of dosimetric parameters related to cardiac sub-structures to be integrated into clinical practice, rather than considering the heart as a whole.

With this in mind, the aim of this study is to define the parameters, particularly dosimetric ones linked to cardiac sub-structures, influencing survival in patients treated with exclusive radiotherapy or radiochemotherapy for esophageal cancer.

Treatment of non-operable esophageal cancers is based on radiochemotherapy, or exclusive radiotherapy.

The cardiac toxicity of radiotherapy in the treatment of thoracic tumor localizations is well documented, however, more and more studies are calling for the use of dosimetric parameters related to cardiac sub-structures to be integrated into clinical practice, rather than considering the heart as a whole.

Although most of these data have been studied in populations with long-term follow-up, such as breast cancer, cardiac toxicity and the reduced survival it entails are also found in diseases such as esophageal cancer.

With this in mind, the aim of this study is to define the parameters, particularly dosimetric ones linked to cardiac sub-structures, influencing survival in patients treated with exclusive radiotherapy or radiochemotherapy for esophageal cancer.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Histologically or cytologically proven esophageal cancer
* Localized or locally advanced esophageal cancer treated with radiochemotherapy or exclusive radiotherapy
* Tumor dose ≥ 50 Gy
* Non-opposition of living patients formulated
* Patient affiliated to a social security scheme

Exclusion Criteria:

* Age \< 18 years
* Patient treated with upfront surgery
* Tumor dose \< 50 Gy
* Other concomitant neoplasia
* Metastatic patient
* Refusal to participate
* Patient under legal protection (guardianship, curatorship, etc...)
Effects of Clinical Interventions for the Management of Late Start

Introduction: Late-onset muscle pain (DOMS) is characterized by a type of temporary muscle damage, common after high-intensity exercise. In addition to pain, DOMS clinically generates muscle stiffness, reduced joint range of motion, muscle weakness and reduced peak torque. In this regard, in order to accelerate the recovery of body systems and treat symptoms of DOMS, the management of different types of interventions has been observed, supporting the clinical practice, based on evidence. Objectives: To investigate the effect of different types of clinical interventions for the treatment of DOMS. Material and methods: For the clinical trial, 50 ultramarathon and rowing athletes of both sexes, aged between 18 and 60 years old, will be recruited randomly into four possible groups: control (CG), shock waves (G1) , massage (G2) and laser therapy (G3). The evaluation moments will be as follows: minutes before exercise (M1); immediately after exercise (M2); immediately after applying the recovery technique (M3); and 24 hours after exercise (M4) and the evaluated outcomes will be: pain, psychological aspects, functional test and blood markers.


Eligibility Criteria:
Inclusion Criteria:

* Professional athletes;
* Age over 18 years;
* Both sexes;
* Not having recent injuries

Exclusion Criteria:

* Participants who do not complete all the proposed collection moments
* who do not agree to participate will be excluded.
Diagnosis of Periodontal Disease Using Genetic Marker in Saliva

The purpose of the present study is to identify the novel periodontal disease biomarkers using differentially expressed microRNA in the saliva. The severity of chronic periodontal diseases and the time of pre- and post-treatment are major classification criteria. The obtained data will secure the foundation for the development of a new non-invasive diagnostic methods for early diagnosis \& prognosis prediction of periodontal disease.


Eligibility Criteria:
Inclusion Criteria:

A. Severe Periodontal Disease

* Patients with chronic severe periodontitis
* Primary treatment of periodontal scaling, subgingival curettage is required, and the general progress of the protocol agreed with the basic periodontal therapy patients.
* subjects agreed collecting saliva and gingival crevicular fluid and physicochemical tests and genetic testing

A. Moderate Periodontal Disease

* Patients with chronic moderate periodontitis
* Primary treatment of periodontal scaling, subgingival curettage is required, and the general progress of the protocol agreed with the basic periodontal therapy patients.
* subjects agreed collecting saliva and gingival crevicular fluid and physicochemical tests and genetic testing

C. Healthy Control

* Healthy periodontal patients ( more than 20 permanent teeth are present , in all parts of deep periodontal pockets measuring 4mm or less, and height is 2mm or less clinical attachment person)
* subjects agreed collecting saliva and gingival crevicular fluid and physicochemical tests and genetic testing

Exclusion Criteria:

* Received periodontal treatment within the last six months
* recently taken antibiotics within 3 months if you need a prescription antibiotic prophylaxis
* taking the drug can affect periodontal status for a long period of time
* pregnant or breastfeeding
* In case of oral inflammatory mucosal disease (Lichen planus, etc.)
* A history of alcoholism or drug abuse if
* other special systemic disease (high blood pressure)
* ages under 18
tDCS in Post-COVID Syndrome: Comparison of Two Targets

The main aim of this study is to compare the effect of two non-invasive neuromodulation targets in patients meeting WHO criteria for the post-COVID condition. A randomized, parallel, double-blind study will be conducted. Patients will receive 15 neuromodulation sessions through transcranial electrical stimulation for 3 weeks, associated with cognitive stimulation during therapy. The main objective will be to evaluate the change in physical fatigue. As secondary objectives, changes in cognition, depression, pain, quality of sleep and quality of life will be evaluated. The objective of this study is to evaluate the effect of two targets (left dorsolateral prefrontal and M1) of the neuromodulation intervention, together with cognitive stimulation.


Eligibility Criteria:
Inclusion Criteria:

* Confirmed diagnosis of COVID-19 at least 6 months before the participation in the study.
* Diagnosis of post-COVID condition according to WHO criteria.
* Age 18-65 years.
* Spanish as native language.
* Sign of written informed consent.

Exclusion Criteria:

* History of stroke
* History of traumatic brain injury or central nervous system infection
* Diagnosis of other neurological or medical disorder that could impact on fatigue.
* Diagnosis of active psychiatric disorder potentially impacting on fatigue or cognitive function.
* Chemotherapy or radiotherapy for cancer.
* Severe sensory deficits (e.g. visual loss) that could limit assessments included int the study protocol.
* Taking drugs or uncontrolled medical disorder potentially causing or worsening fatigue. Specifically, uncontrolled adrenal insufficiency, miastenic syndromes, thyroid disorders, cardiac failure, chronic kidney disorders and neurodegenerative disorders are excluded.
* History of abuse of alcohol or other toxics.
* Any contraindication for transcranial electric stimulation: epilepsy, pregnancy, metallic implants, brain devices, pacemakers, head injuries).
Acute Effects of Heat, Cold and Stretching on Knee Proprioception and Vertical Jump

The aim of our study is to investigate the effects of heat, cold and stretching on knee proprioception and vertical jump. 60 healthy individuals were randomized into hot, cold, stretching and control groups of 15 each. Pre-test and post-test measurements were made immediately after the application. Knee proprioception was measured with a digital goniometer using the EPD (joint position sense) test. Vertical jump heights were measured with contact mat by countermovement (CMJ) and squat splash (SQS) tests.


Eligibility Criteria:
Inclusion Criteria:

* Being between the ages of 18-30
* Agreeing to participate in the study and being informed Approving the Volunteer Consent Form

Exclusion Criteria:

* Having a history of surgery in the knee area
* Movement in lower extremity joints that may affect measurements have limitations.
* Having vision, hearing and balance impairment.
* May cause peripheral neuropathy and deep sensory loss, or loss of proprioception may be caused by other mechanisms having diseases.
* Have a neurological or systemic disease that affects balance and coordination have.
* Describing very severe pain in any part of the lower extremity.
* Being pregnant.
* Having cognitive dysfunction, lack of cooperation
* Having any disease that may cause inability to dry
Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)

This study was designed to assess the safety and efficacy of GW813893 in the prophylaxis of VTE following TKR and to provide evidence to enable the selection of the appropriate dose(s) and dose regimen of GW813893 for future investigation.


Eligibility Criteria:
Inclusion criteria:

* Patients who are scheduled for primary elective unilateral total knee arthroplasty.

Exclusion criteria:

* Women who are not surgically sterile or post-menopausal
* Have a contra-indication to contract venography
* Have a known disorder associated with increased risk of bleeding or have been immobile up to 12 weeks before surgery.